PT  - JOURNAL ARTICLE
AU  - DE LA GARZA RAMOS, RAFAEL
AU  - NAKHLA, JONATHAN
AU  - BHASHYAM, NIKETH
AU  - AMMAR, ADAM E.
AU  - SCOCO, ALEKA N.
AU  - KINON, MERRIT D.
AU  - YASSARI, REZA
TI  - Trends in the Use of Bone Morphogenetic Protein–2 in Adult Spinal Deformity Surgery: A 10-Year Analysis of 54 054 Patients
AID  - 10.14444/5054
DP  - 2018 Aug 01
TA  - International Journal of Spine Surgery
PG  - 453--459
VI  - 12
IP  - 4
4099  - https://www.ijssurgery.com/content/12/4/453.short
4100  - https://www.ijssurgery.com/content/12/4/453.full
SO  - Int J Spine Surg2018 Aug 01; 12
AB  - Background: Bone morphogenetic protein–2 (BMP-2) is an available bone graft option in spinal fusion surgery. The purpose of this study is to investigate the trends of BMP-2 utilization in adult spinal deformity (ASD) surgery. Methods: The Nationwide Inpatient Sample database from 2002 to 2011 was reviewed. Inclusion criteria were patients over 18 years of age who underwent spinal fusion for ASD. Trends of BMP-2 use were examined over time, as well as stratified based on patient and surgical characteristics. All analyses were done after application of discharge weights to produce national estimates.Results: There were 54 054 patients who met inclusion criteria and were included in this study. The overall rate of BMP-2 use was 39.7% (95% confidence interval 35.0%- 44.3%). Overall, there was steady increase in its use over time, with the highest peak in 2009 (55.3% of all cases used BMP-2), and then a decrease up to 37.9% in 2011 (P < .001). The rate of BMP-2 use was significantly higher for patients older than 54 years of age (compared to patients <54, P < .001). It was also higher in females (P = .009), Caucasian patients (P = .006), and Medicare patients (P = .006). Its use was 28.6% in the Northeast, 38.1% in the South, 45.2% in the Midwest, and 48.2% in the West (P = .035). Circumferential procedures had the highest rate of BMP-2 use (44.3%, P = .045). Average total hospital charges were $152,403 ± 117,454 for patients who did not receive BMP-2 and $205,426 ± 137,561 for patients who did (P < .001).Conclusion After analysis of a large nationwide database, it was found that the rate of BMP-2 use in ASD surgery is approximately 40%. There was a significant increase in use from 2002 to 2009, and a decrease thereafter. The highest rates of use were found in older patients, female patients, white patients, Medicare patients, circumferential approaches, and patients undergoing surgery in the Midwest and West regions.